Teva invested $10M in Heptares Therapeutics

A licensing and drug-discovery agreement with UK-based Heptares Therapeutics, a unit of Sosei Group Corporation under which it will receive exclusive global rights to develop, manufacture and commercialize small-molecule calcitonin gene-related peptide (CGRP) antagonists for the treatment of migraine headaches, was signed by Israeli pharmaceutical giant Teva. Based on this agreement, Heptares will receive a payment-investment of 10 million dollars.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More